{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:42:39Z","timestamp":1786725759340,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pyrotinib, a novel irreversible pan-HER tyrosine kinase inhibitor, has been approved for the treatment of HER2-positive metastatic breast cancer in China. The aim of this study was to evaluate the efficacy and safety of pyrotinib in advanced nonsmall cell lung cancer (NSCLC) patients with HER2 alterations in real-world practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis of advanced NSCLC with HER2 mutations or amplifications who received pyrotinib-based treatment at the Qilu Hospital in Shandong University was performed. The primary end points were objective response rate and safety. The secondary end points were progression-free survival, disease control rate, and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty three eligible patients from a single center were enrolled between June 2019 and March 2023; among them, 21 had HER2 mutation and two harbored HER2 amplification. Evaluation of the efficacy in 21 patients revealed an objective response rate of 28.6% (6\/21; 95% confidence interval [CI]: 7.5%-49.6%) and disease control rate of 85.7% (18\/21). The median progression-free survival and overall survival were 7.7 months (95% CI: 6.07-9.33) and 20.8 months (95% CI: 8.42-33.18), respectively. The most common adverse events (AEs) included diarrhea (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 14, 60.9%), nausea (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5, 21.7%), and liver dysfunction (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5, 21.7%). Seven patients (7\/23, 30.4%) had grade 3-4 AE; no grade 5 AE was observed. Furthermore, one patient (1\/23, 4.3%) experienced dose withdrawal and two (2\/23, 8.7%) presented with dose reduction symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pyrotinib-based therapy showed promising antitumor activity and acceptable safety in advanced NSCLC patients with HER2 alterations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1268_23","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T10:10:46Z","timestamp":1703844646000},"page":"1663-1668","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of a pyrotinib-based regimen in non-small cell lung cancer patients harboring HER2 alterations: A real-world retrospective study"],"prefix":"10.4103","volume":"19","author":[{"given":"Xiangling","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"R1-20260511","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/0973-1482.180605","article-title":"Genomic aberrations in non- small cell lung cancer and their impact on treatment outcome","volume":"13","author":"Mohammed","year":"2017","journal-title":"J Cancer Res Ther"},{"key":"R2-20260511","doi-asserted-by":"crossref","first-page":"e1303","DOI":"10.1634\/theoncologist.2018-0845","article-title":"Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers","volume":"24","author":"Subramanian","year":"2019","journal-title":"Oncologist"},{"key":"R3-20260511","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1158\/1078-0432.CCR-05-0976","article-title":"Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas","volume":"12","author":"Lee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R4-20260511","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/cncr.30869","article-title":"HER2 mutations in lung adenocarcinomas: A report from the lung cancer mutation consortium","volume":"123","author":"Pillai","year":"2017","journal-title":"Cancer"},{"key":"R5-20260511","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazi\u00e8res","year":"2013","journal-title":"J Clin Oncol"},{"key":"R6-20260511","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.lungcan.2011.01.014","article-title":"Prognostic and predictive implications of HER2\/ERBB2\/neu gene mutations in lung cancers","volume":"74","author":"Tomizawa","year":"2011","journal-title":"Lung Cancer"},{"key":"R7-20260511","doi-asserted-by":"crossref","first-page":"114371","DOI":"10.18632\/oncotarget.22825","article-title":"Genomic alterations of ERBB receptors in cancer: Clinical implications","volume":"8","author":"Mishra","year":"2017","journal-title":"Oncotarget"},{"key":"R8-20260511","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jncc.2021.04.001","article-title":"Targeting HER2 genomic alterations in non-small cell lung cancer","volume":"1","author":"Zeng","year":"2021","journal-title":"J Natl Cancer"},{"issue":"Supplement","key":"R9-20260511","doi-asserted-by":"crossref","first-page":"C131","DOI":"10.4103\/0973-1482.200613","article-title":"Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"R10-20260511","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial","volume":"40","author":"Le","year":"2022","journal-title":"J Clin Oncol"},{"key":"R11-20260511","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"R12-20260511","first-page":"1033","article-title":"Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography\/quadrupole time-of-flight mass spectrometry","author":"Zhu","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R13-20260511","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejps.2017.01.021","article-title":"Discovery and development of pyrotinib: A novel irreversible EGFR\/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer","volume":"110","author":"Li","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"R14-20260511","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.19.00108","article-title":"Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and\/or trastuzumab: A randomized, phase II study","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"key":"R15-20260511","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): A multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol"},{"key":"R16-20260511","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/tbcr-20-25","article-title":"Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): A randomized, double-blind, placebo-controlled phase 3 study","volume":"1","author":"Yan","year":"2020","journal-title":"Transl Breast Cancer Res"},{"key":"R17-20260511","doi-asserted-by":"crossref","first-page":"13479","DOI":"10.2147\/CMAR.S281765","article-title":"Studies on the safety and efficacy of pyrotinib in the treatment of HER2- positive advanced solid tumors excluding breast cancer","volume":"12","author":"Yin","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R18-20260511","first-page":"4233782","article-title":"Retrospective study on the efficacy and safety of pyrotinib-based therapy for HER2-positive nonbreast advanced solid tumors","volume":"2022","author":"Wang","year":"2022","journal-title":"J Oncol"},{"key":"R19-20260511","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1200\/JCO.2020.38.15_suppl.553","article-title":"Next-generation sequencing (NGS) identifies a new breast cancer subtype with HER2 low-amplification status as a candidate for targeted therapy","volume":"38","author":"Zhang","year":"2020","journal-title":"J Clin Oncol"},{"key":"R20-20260511","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2019.02.017","article-title":"Afatinib in NSCLC with HER2 mutations: Results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP)","volume":"14","author":"Dziadziuszko","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R21-20260511","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2015.01.013","article-title":"Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma","volume":"88","author":"De Gr\u00e8ve","year":"2015","journal-title":"Lung Cancer"},{"key":"R22-20260511","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1016\/j.jtho.2016.11.398","article-title":"MA04.02 Neratinib\u00b1Temsirolimus in HER2-mutant lung cancers: An international, randomized phase II study","volume":"12","author":"Gandhi","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"Supplement 5","key":"R23-20260511","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdu438.47","article-title":"Neratinib (N) with or without Temsirolimus (Tem) in patients (Pts) with non-small cell lung cancer (Nsclc) carrying Her2 somatic mutations: An international randomized phase II study","volume":"25","author":"Besse","year":"2014","journal-title":"Annals of Oncology"},{"key":"R24-20260511","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.21.01113","article-title":"Poziotinib for patients with HER2 exon 20 mutant non-small-cell lung cancer: Results from a phase II trial","volume":"40","author":"Elamin","year":"2022","journal-title":"J Clin Oncol"},{"key":"R25-20260511","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.20.00297","article-title":"Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: A multicenter, open-label, single-arm, phase II study","volume":"38","author":"Zhou","year":"2020","journal-title":"J Clin Oncol"},{"key":"R26-20260511","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1158\/1078-0432.CCR-21-2936","article-title":"Pyrotinib in patients with HER2-amplified advanced non-small cell lung cancer: A prospective, multicenter, single-arm trial","volume":"28","author":"Song","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R27-20260511","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jncc.2021.08.001","article-title":"Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: A retrospective real-world study (PEARL)","volume":"1","author":"Yang","year":"2021","journal-title":"J Natl Cancer Center"},{"key":"R28-20260511","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12916-022-02245-z","article-title":"Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: A multicenter, single-arm, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med"},{"key":"R29-20260511","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1111\/bcp.15155","article-title":"Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis","volume":"88","author":"Wu","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R30-20260511","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1634\/theoncologist.2019-0547","article-title":"Mutation variants and co-mutations as genomic modifiers of response to afatinib in HER2-mutant lung adenocarcinoma","volume":"25","author":"Fang","year":"2020","journal-title":"Oncologist"},{"key":"R31-20260511","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jtho.2020.01.020","article-title":"Conformational landscapes of HER2 Exon 20 insertions explain their sensitivity to kinase inhibitors in lung adenocarcinoma","volume":"15","author":"Zhao","year":"2020","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1268_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:25:14Z","timestamp":1786724714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1268_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1268_23","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"2023-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}